Real-world evidence solution market Trends & Forecast Report 2026

1
Real-world evidence solution market
2
Global Real-World Evidence Solutions market has
gained momentum in recent years with a CAGR of
16.5, in value terms, over the forecast period
2020-2026, and is expected to reach USD 3,321.7
million by 2026. The growth is due to the shift
from volume to value-based care, increasing aging
population and prevalence of chronic diseases and
delays in drug development, and the subsequent
increase in development costs. Besides, the
real-world data sets are widely adopted by
end-users for RWE for various applications such
as drug development approvals, market access
reimbursement/coverage decisions, clinical
decision-making, and medical device development
approvals, among others, that helps in the growth
of the overall market. Therapeutic segment
contributing major share to drive the real-world
evidence solution market. Based on the
therapeutic area, the real-world evidence market
is broadly categorized into oncology, immunology,
neurology, cardiovascular disease, and other
therapeutic areas the oncology segment has been
accounted for the largest share of the real-world
evidence market. The large share of this segment
can be attributed to the high number of clinical
trials conducted for oncology and the rising
prevalence of cancer worldwide.
3
Rising in the investment market to create market
opportunities in upcoming years. A rise in
investment creates new opportunities in the
market. For instance, Syapse, a San Francisco,
CA-based provider of precision oncology solutions
announced USD 30 million in new equity funding to
accelerate the creation and use of real-world
evidence (RWE) in oncology led by Revelation
Alpine, LLC, with participation from existing
investors including Amgen Ventures, Ascension
Ventures, Intermountain Ventures, Merck Global
Health Innovation Fund, Roche Finance Ltd,
Safeguard Scientifics and Social Capital.
Revelation Alpines Managing Partner Zack Scott,
MD will join the Syapse Board of Directors.
Syapse collaborates with life sciences companies
to provide insights from real-world data through
its portfolio of products to support research and
product development, clinical trials patient
matching, real-world evidence regulatory filings,
and monitoring of commercially approved products.
Syapse supports health systems with insights to
support health systems large-scale precision
medicine programs through integrating the
clinical, molecular, and outcomes data they need
to make the most informed treatment
decisions. Read More https//www.blueweaveconsu
lting.com/global-real-world-evidence-solutions-mar
ket-bwc19297